Usuario:Ana cecilia franco/Taller
Alan Hutchison Fairlamb, CBE, FRSE, FLS, FMedSci, FSB (born 30 April 1947, Newcastle upon Tyne, England) is a Wellcome Trust Principal Research Fellow and Professor of Biochemistry in the Division of Biological Chemistry and Drug Discovery at the University of Dundee, Scotland. From 2006-2011 he was a member of the Scientific and Technical Advisory Committee of the Special Programme for Research and Training in Tropical Diseases (TDR) -- an independent global programme of scientific collaboration co-sponsored by UNICEF, UNDP, the World Bank and WHO. Currently he is a member of the governing board of the Tres Cantos Open Lab Foundation, whose aim is to accelerate the discovery and development of medicines to tackle diseases of the developing world in an open collaborative manner.
Professor Alan Fairlamb, y su equipo--and his team study the protozoan parasites causing three different diseases y su equipo estudio llos tres diiferentes tipos de protozoario causantes de enfermedades- sleeping sickness, Chagas disease and leishmaniasis. He was one of the 250 scientists involved in the el fue uno de los 250 cientificos involucrados en genome sequencing of these parasites.[1]
In 1985, Alan Fairlamb discovered a unique ----en 1985 alan fairlamb descubrio un unico componente presente en esos parásitos y lo nobró trypanothienell--thiol compound present in these parasites, and named it trypanothione.[2] This thiol metabolite is quite different from its human equivalent, glutathione. Trypanothione allows the parasites to fend off free radicals and other toxic oxidants produced by the immune system of the infected patient, and was shown to be vital for parasite surviv y exhibio ser al and virulence.[3] For instance, antimonials neutralize the Leishmania parasite’s antioxidant defence system, allowing the patient to clear the infection.[4] Studies on the effect of drugs on trypanothione metabolism resulted in the discovery that fexinidzole is a potential oral treatment for visceral leishmaniasis.[5]
Since 2006, desde 2006 Alan Fairlamb and Mike Ferguson han estado co dirigiendo have been co-directors of the Drug Discovery Unit at the University of Dundee. The new centre, opened in 2005, has facilities for high-throughput screening and medicinal chemistry.[6] These will take the drug discovery/development process further than any other UK university, to a stage where pharmaceutical companies will have sufficient data to move into the production stage.
References
editar- ↑ Berriman M, Ghedin E, Hertz-Fowler C, et al (2005). «The genome of the African trypanosome Trypanosoma brucei». Science 309 (5733): 416-22. Bibcode:2005Sci...309..416B. PMID 16020726. doi:10.1126/science.1112642.
- ↑ Fairlamb AH, Blackburn P, Ulrich P, Chait BT, Cerami A (1985). «Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids». Science 227 (4693): 1485-7. Bibcode:1985Sci...227.1485F. PMID 3883489. doi:10.1126/science.3883489.
- ↑ Krieger S, Schwarz W, Ariyanayagam MR, Fairlamb AH, Krauth-Siegel RL, Clayton C (2000). «Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress». Mol. Microbiol. 35 (3): 542-52. PMID 10672177. doi:10.1046/j.1365-2958.2000.01721.x.
- ↑ Wyllie S, Cunningham ML, Fairlamb AH (2004). «Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani». J. Biol. Chem. 279 (38): 39925-32. PMID 15252045. doi:10.1074/jbc.M405635200.
- ↑ Wyllie,S., Patterson,S., Stojanovski,L., Simeons,F.R., Norval,S., Kime,R., Read,K.D. and Fairlamb AH (2012). «The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.». Sci. Transl. Med. 4: 119re1. PMC 3457684. PMID 22301556. doi:10.1126/scitranslmed.3003326.
- ↑ University hunts cure for parasitic infections Tim Radford, The Guardian, Wednesday October 26, 2005
External links
editar